Correlation Between Ideaya Biosciences and Mineralys Therapeutics,

Can any of the company-specific risk be diversified away by investing in both Ideaya Biosciences and Mineralys Therapeutics, at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Ideaya Biosciences and Mineralys Therapeutics, into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Ideaya Biosciences and Mineralys Therapeutics, Common, you can compare the effects of market volatilities on Ideaya Biosciences and Mineralys Therapeutics, and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Ideaya Biosciences with a short position of Mineralys Therapeutics,. Check out your portfolio center. Please also check ongoing floating volatility patterns of Ideaya Biosciences and Mineralys Therapeutics,.

Diversification Opportunities for Ideaya Biosciences and Mineralys Therapeutics,

0.74

Correlation Coefficient

Ideaya Biosciences  Mineralys Therapeutics,

Poor diversification

The 3 months correlation between Ideaya and Mineralys is 0.74. Overlapping area represents the amount of risk that can be diversified away by holding Ideaya Biosciences and Mineralys Therapeutics, Common in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Mineralys Therapeutics, and Ideaya Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Ideaya Biosciences are associated (or correlated) with Mineralys Therapeutics,. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Mineralys Therapeutics, has no effect on the direction of Ideaya Biosciences i.e., Ideaya Biosciences and Mineralys Therapeutics, go up and down completely randomly.

Pair Corralation between Ideaya Biosciences and Mineralys Therapeutics,

Given the investment horizon of 90 days Ideaya Biosciences is expected to under-perform the Mineralys Therapeutics,. But the stock apears to be less risky and, when comparing its historical volatility, Ideaya Biosciences is 1.5 times less risky than Mineralys Therapeutics,. The stock trades about -0.08 of its potential returns per unit of risk. The Mineralys Therapeutics, Common is currently generating about -0.01 of returns per unit of risk over similar time horizon. If you would invest  1,351  in Mineralys Therapeutics, Common on October 6, 2024 and sell it today you would lose (76.00) from holding Mineralys Therapeutics, Common or give up 5.63% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Ideaya Biosciences  vs.  Mineralys Therapeutics, Common

Ideaya Biosciences

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Ideaya Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest weak performance, the Stock's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the company investors.

Mineralys Therapeutics,

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Mineralys Therapeutics, Common has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of comparatively stable basic indicators, Mineralys Therapeutics, is not utilizing all of its potentials. The current stock price uproar, may contribute to short-horizon losses for the private investors.

Pair Trading with Ideaya Biosciences and Mineralys Therapeutics,

The main advantage of trading using opposite Ideaya Biosciences and Mineralys Therapeutics, positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Ideaya Biosciences position performs unexpectedly, Mineralys Therapeutics, can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Mineralys Therapeutics, will offset losses from the drop in Mineralys Therapeutics,'s long position.

The idea behind Ideaya Biosciences and Mineralys Therapeutics, Common pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Portfolio Comparator module to compare the composition, asset allocations and performance of any two portfolios in your account.